The January 10, 2019, article by Pennell et al entitled “SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor–Mutant Non–Small-Cell Lung Cancer” (Journal of Clinical Oncology 37:97-104, 2019) was published with an error.
In the AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST section, Daniel B. Costa’s disclosures were recorded as
“Honoraria: Takeda
Consulting or Advisory Role: AstraZeneca.”
They should have been recorded as:
“Honoraria: Takeda/Millennium Pharmaceuticals, Pfizer
Consulting or Advisory Role: AstraZeneca, Takeda/Millennium Pharmaceuticals
Research Funding: Genentech (Inst), Takeda/Millennium Pharmaceuticals (Inst), AstraZeneca (Inst), Pfizer (Inst), Merck (Inst), Merrimack (Inst), Bristol-Myers Squibb (Inst), Clovis Oncology (Inst).”
This has been corrected as of February 5, 2019. The authors apologize for the errors.